Bevacizumab beyond disease progression after first‐line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non–small cell lung cancer (<scp>W</scp>est <scp>J</scp>apan <scp>O</scp>ncology <scp>G</scp>roup 5910L): An open‐label, randomized, phase 2 trialMasayuki Takeda, Isamu Okamoto, Takeharu Yamanaka et al.|Cancer|2016Cited by 42
Adoptive Immunotherapy of Cancer using Activated Autologous Lymphocytes -Current Status and New Strategies-Yoshiyuki Yamaguchi, Tetsuya Toge, Akiko Ohshita et al.|Human Cell|2003Cited by 32
Locoregional immunotherapy of malignant ascites from gastric cancer using DTH-oriented doses of the streptococcal preparation OK-432: Treatment of Th1 dysfunction in the ascites microenvironmentYoshiyuki Yamaguchi, Tetsuya Toge, Akiko Ohshita et al.|International Journal of Oncology|2004Cited by 16
Novel system for generating cytotoxic effector lymphocytes using carcinoembryonic antigen (CEA) peptide and cultured dendritic cells.Koji Ohta, Tetsuya Toge, Yoshiyuki Yamaguchi et al.|PubMed|2003Cited by 13
Polyglycolic acid mesh for preventing post-thoracoscopic bullectomy recurrenceEiji Miyahara, Tsuneo Okumichi, Daisuke Ueda et al.|Surgery Today|2021Cited by 8